Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK5 | Q8IW41 | 2/20 | 0.40 |
| ▸ | TTK | P33981 | 2/20 | 0.39 |
| ▸ | EGLN2 | Q96KS0 | 4/20 | 0.36 |
| ▸ | IKBKB | O14920 | 5/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 3/20 | 0.34 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.34 |
| ▸ | CHUK | O15111 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL274498 | 0.85 | MAPKAPK5 (0.42) | MAPKAPK5TTKEGLN2MKNK1FYN | |
| SCHEMBL274888 | 0.83 | MAPKAPK5 (0.58) | MAPKAPK5TTKEGLN2MKNK1 | |
| SCHEMBL274671 | 0.81 | MAPKAPK5 (0.42) | MAPKAPK5TTK | |
| SCHEMBL275197 | 0.79 | MAPKAPK5 (0.40) | MAPKAPK5TTKEGLN2IKBKBFYN | |
| SCHEMBL2394082 | 0.69 | MAPKAPK5 (0.47) | MAPKAPK5TTK | |
| SCHEMBL275076 | 0.69 | FLT3 (0.42) | MAPKAPK5TTK | |
| SCHEMBL273764 | 0.69 | MAPKAPK5 (0.61) | MAPKAPK5MKNK1 | |
| SCHEMBL274499 | 0.67 | MAPKAPK5 (0.62) | MAPKAPK5MKNK1 | |
| SCHEMBL279913 | 0.67 | MAPKAPK5 (0.57) | MAPKAPK5TTK | |
| SCHEMBL279828 | 0.67 | MAPKAPK5 (0.57) | MAPKAPK5TTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | claimed |
| US-8133895-B2 | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-03-13 | — | — | US | disclosed |
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | GALAPAGOS, N.V. (BE) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131446-A1 | Fused pyrazine compounds useful for the treatment of degenerative and inflmmatory diseases | NOD1, TNF, NOD2 | MAPKAPK5 1247/4885TTK 4697/4885EGLN2 2621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.